Literature DB >> 27048885

Andexanet: Effectively Reversing Anticoagulation.

Giuseppe Lippi1, Fabian Sanchis-Gomar2, Emmanuel J Favaloro3.   

Abstract

Despite direct oral anticoagulants becoming a mainstay of anticoagulant therapy, the effective, timely, and safe reversal of their anticoagulant effect remains challenging. Emerging evidence attests that andexanet, a recombinant and inactive variant of native factor X (FXa), competitively inhibits and counteracts the anticoagulant effect of many inhibitors of native activated FXa.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticoagulants; andexanet; antidote; apixaban; rivaroxaban

Mesh:

Substances:

Year:  2016        PMID: 27048885     DOI: 10.1016/j.tips.2016.03.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  4 in total

1.  Laboratory monitoring of direct oral anticoagulants (DOACs)-The perfect storm?

Authors:  Giuseppe Lippi; Emmanuel J Favaloro
Journal:  Ann Transl Med       Date:  2017-01

Review 2.  Andexanet Alfa: First Global Approval.

Authors:  Young-A Heo
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 3.  Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation.

Authors:  Elise Carpenter; Divita Singh; Eric Dietrich; John Gums
Journal:  Ther Adv Drug Saf       Date:  2019-11-26

4.  Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation.

Authors:  Fabián Santana-Romo; Carlos F Lagos; Yorley Duarte; Francisco Castillo; Yanina Moglie; Miguel A Maestro; Nitin Charbe; Flavia C Zacconi
Journal:  Molecules       Date:  2020-01-23       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.